The  ||| S:0 E:4 ||| DT
role  ||| S:4 E:9 ||| NN
of  ||| S:9 E:12 ||| IN
carbocystein  ||| S:12 E:25 ||| NN
in  ||| S:25 E:28 ||| IN
the  ||| S:28 E:32 ||| DT
treatment  ||| S:32 E:42 ||| NN
of  ||| S:42 E:45 ||| IN
sinusitis  ||| S:45 E:55 ||| JJ
Chronic  ||| S:55 E:63 ||| JJ
sinusitis  ||| S:63 E:73 ||| NN
is  ||| S:73 E:76 ||| VBZ
one  ||| S:76 E:80 ||| CD
of  ||| S:80 E:83 ||| IN
the  ||| S:83 E:87 ||| DT
most  ||| S:87 E:92 ||| RBS
common  ||| S:92 E:99 ||| JJ
presenting  ||| S:99 E:110 ||| JJ
complaints  ||| S:110 E:121 ||| NNS
of  ||| S:121 E:124 ||| IN
all  ||| S:124 E:128 ||| DT
doctor  ||| S:128 E:135 ||| NN
visits  ||| S:135 E:142 ||| NNS
in  ||| S:142 E:145 ||| IN
the  ||| S:145 E:149 ||| DT
United  ||| S:149 E:156 ||| NNP
States  ||| S:156 E:163 ||| NNPS
and  ||| S:163 E:167 ||| CC
Europe ||| S:167 E:173 ||| NNP
,  ||| S:173 E:175 ||| ,
with  ||| S:175 E:180 ||| IN
more  ||| S:180 E:185 ||| JJR
than  ||| S:185 E:190 ||| IN
13 ||| S:190 E:192 ||| CD
%  ||| S:192 E:194 ||| NN
of  ||| S:194 E:197 ||| IN
people  ||| S:197 E:204 ||| NNS
affected  ||| S:204 E:213 ||| VBN
in  ||| S:213 E:216 ||| IN
any  ||| S:216 E:220 ||| DT
given  ||| S:220 E:226 ||| VBN
year ||| S:226 E:230 ||| NN
.  ||| S:230 E:232 ||| .
This  ||| S:232 E:237 ||| DT
disease  ||| S:237 E:245 ||| NN
has  ||| S:245 E:249 ||| VBZ
a  ||| S:249 E:251 ||| DT
wide  ||| S:251 E:256 ||| JJ
range  ||| S:256 E:262 ||| NN
of  ||| S:262 E:265 ||| IN
impact  ||| S:265 E:272 ||| NN
on  ||| S:272 E:275 ||| IN
communities ||| S:275 E:286 ||| NNS
.  ||| S:286 E:288 ||| .
Patients  ||| S:288 E:297 ||| NNS
with  ||| S:297 E:302 ||| IN
recurrent  ||| S:302 E:312 ||| NN
or  ||| S:312 E:315 ||| CC
chronic  ||| S:315 E:323 ||| JJ
sinusitis  ||| S:323 E:333 ||| NNS
report  ||| S:333 E:340 ||| VBP
a  ||| S:340 E:342 ||| DT
deteriorative  ||| S:342 E:356 ||| JJ
sense  ||| S:356 E:362 ||| NN
of  ||| S:362 E:365 ||| IN
general  ||| S:365 E:373 ||| JJ
health  ||| S:373 E:380 ||| NN
and  ||| S:380 E:384 ||| CC
vitality ||| S:384 E:392 ||| NN
,  ||| S:392 E:394 ||| ,
when  ||| S:394 E:399 ||| WRB
compared  ||| S:399 E:408 ||| VBN
to  ||| S:408 E:411 ||| TO
general  ||| S:411 E:419 ||| JJ
population ||| S:419 E:429 ||| NN
.  ||| S:429 E:431 ||| .
In  ||| S:431 E:434 ||| IN
our  ||| S:434 E:438 ||| PRP$
Department  ||| S:438 E:449 ||| NNP
we  ||| S:449 E:452 ||| PRP
perform  ||| S:452 E:460 ||| VBP
about  ||| S:460 E:466 ||| RB
600  ||| S:466 E:470 ||| CD
functional  ||| S:470 E:481 ||| FW
endoscopic  ||| S:481 E:492 ||| FW
sinus  ||| S:492 E:498 ||| FW
surgeries  ||| S:498 E:508 ||| FW
( ||| S:508 E:509 ||| -LRB-
FESS ||| S:509 E:513 ||| NNP
)  ||| S:513 E:515 ||| -RRB-
per  ||| S:515 E:519 ||| IN
year ||| S:519 E:523 ||| NN
.  ||| S:523 E:525 ||| .
Chronic  ||| S:525 E:533 ||| JJ
rhinosinusitis  ||| S:533 E:548 ||| NN
represents  ||| S:548 E:559 ||| VBZ
a  ||| S:559 E:561 ||| DT
spectrum  ||| S:561 E:570 ||| NN
of  ||| S:570 E:573 ||| IN
inflammatory  ||| S:573 E:586 ||| JJ
and  ||| S:586 E:590 ||| CC
infectious  ||| S:590 E:601 ||| JJ
processes  ||| S:601 E:611 ||| NNS
concurrently  ||| S:611 E:624 ||| VBP
affecting  ||| S:624 E:634 ||| VBG
the  ||| S:634 E:638 ||| DT
nose  ||| S:638 E:643 ||| NN
and  ||| S:643 E:647 ||| CC
paranasal  ||| S:647 E:657 ||| JJ
sinuses ||| S:657 E:664 ||| NN
.  ||| S:664 E:666 ||| .
Among  ||| S:666 E:672 ||| IN
chronic  ||| S:672 E:680 ||| JJ
paranasal  ||| S:680 E:690 ||| NNS
sinusitis  ||| S:690 E:700 ||| VBP
one  ||| S:700 E:704 ||| PRP
must  ||| S:704 E:709 ||| MD
single  ||| S:709 E:716 ||| VB
out  ||| S:716 E:720 ||| RP
paranasal  ||| S:720 E:730 ||| JJ
sinusitis  ||| S:730 E:740 ||| NN
with  ||| S:740 E:745 ||| IN
and  ||| S:745 E:749 ||| CC
without  ||| S:749 E:757 ||| IN
polyps ||| S:757 E:763 ||| NNS
.  ||| S:763 E:765 ||| .
In  ||| S:765 E:768 ||| IN
the  ||| S:768 E:772 ||| DT
paranasal  ||| S:772 E:782 ||| JJ
sinusitis  ||| S:782 E:792 ||| NNS
patomechanism  ||| S:792 E:806 ||| VBP
the  ||| S:806 E:810 ||| DT
blockage  ||| S:810 E:819 ||| NN
of  ||| S:819 E:822 ||| IN
natural  ||| S:822 E:830 ||| JJ
ostium  ||| S:830 E:837 ||| NN
plays  ||| S:837 E:843 ||| VBZ
one  ||| S:843 E:847 ||| CD
of  ||| S:847 E:850 ||| IN
the  ||| S:850 E:854 ||| DT
most  ||| S:854 E:859 ||| RBS
important  ||| S:859 E:869 ||| JJ
roles ||| S:869 E:874 ||| NNS
.  ||| S:874 E:876 ||| .
The  ||| S:876 E:880 ||| DT
closure  ||| S:880 E:888 ||| NN
of  ||| S:888 E:891 ||| IN
sinus  ||| S:891 E:897 ||| JJ
proper  ||| S:897 E:904 ||| JJ
ventilation  ||| S:904 E:916 ||| NN
passages  ||| S:916 E:925 ||| NN
leads  ||| S:925 E:931 ||| VBZ
to  ||| S:931 E:934 ||| TO
the  ||| S:934 E:938 ||| DT
triggering  ||| S:938 E:949 ||| NN
of  ||| S:949 E:952 ||| IN
many  ||| S:952 E:957 ||| JJ
pathological  ||| S:957 E:970 ||| JJ
occurrences  ||| S:970 E:982 ||| NNS
within  ||| S:982 E:989 ||| IN
mucous  ||| S:989 E:996 ||| JJ
membrane  ||| S:996 E:1005 ||| NN
of  ||| S:1005 E:1008 ||| IN
this  ||| S:1008 E:1013 ||| DT
region ||| S:1013 E:1019 ||| NN
.  ||| S:1019 E:1021 ||| .
The  ||| S:1021 E:1025 ||| DT
treatment  ||| S:1025 E:1035 ||| NN
of  ||| S:1035 E:1038 ||| IN
paranasal  ||| S:1038 E:1048 ||| JJ
sinusitis  ||| S:1048 E:1058 ||| NN
is  ||| S:1058 E:1061 ||| VBZ
diversified  ||| S:1061 E:1073 ||| VBN
and  ||| S:1073 E:1077 ||| CC
involves  ||| S:1077 E:1086 ||| VBZ
a  ||| S:1086 E:1088 ||| DT
surgical  ||| S:1088 E:1097 ||| JJ
procedure  ||| S:1097 E:1107 ||| NN
as  ||| S:1107 E:1110 ||| IN
well  ||| S:1110 E:1115 ||| RB
as  ||| S:1115 E:1118 ||| IN
anti-inflammatory  ||| S:1118 E:1136 ||| JJ
and  ||| S:1136 E:1140 ||| CC
antiallergic  ||| S:1140 E:1153 ||| JJ
drugs  ||| S:1153 E:1159 ||| NNS
( ||| S:1159 E:1160 ||| -LRB-
medications ||| S:1160 E:1171 ||| LS
)  ||| S:1171 E:1173 ||| -RRB-
and  ||| S:1173 E:1177 ||| CC
mucolytics ||| S:1177 E:1187 ||| NN
.  ||| S:1187 E:1189 ||| .
Its  ||| S:1189 E:1193 ||| PRP$
purpose  ||| S:1193 E:1201 ||| NN
is  ||| S:1201 E:1204 ||| VBZ
to  ||| S:1204 E:1207 ||| TO
clear  ||| S:1207 E:1213 ||| VB
the  ||| S:1213 E:1217 ||| DT
nose  ||| S:1217 E:1222 ||| NN
through  ||| S:1222 E:1230 ||| IN
the  ||| S:1230 E:1234 ||| DT
elimination  ||| S:1234 E:1246 ||| NN
of  ||| S:1246 E:1249 ||| IN
bacterial  ||| S:1249 E:1259 ||| JJ
infection ||| S:1259 E:1268 ||| NN
,  ||| S:1268 E:1270 ||| ,
liquidating  ||| S:1270 E:1282 ||| VBG
and  ||| S:1282 E:1286 ||| CC
removal  ||| S:1286 E:1294 ||| NN
of  ||| S:1294 E:1297 ||| IN
lying  ||| S:1297 E:1303 ||| VBG
discharge  ||| S:1303 E:1313 ||| NN
and  ||| S:1313 E:1317 ||| CC
the  ||| S:1317 E:1321 ||| DT
restoration  ||| S:1321 E:1333 ||| NN
of  ||| S:1333 E:1336 ||| IN
the  ||| S:1336 E:1340 ||| DT
proper  ||| S:1340 E:1347 ||| JJ
muco-ciliary  ||| S:1347 E:1360 ||| JJ
transportation ||| S:1360 E:1374 ||| NN
,  ||| S:1374 E:1376 ||| ,
and  ||| S:1376 E:1380 ||| CC
through  ||| S:1380 E:1388 ||| IN
this  ||| S:1388 E:1393 ||| DT
the  ||| S:1393 E:1397 ||| DT
improvement  ||| S:1397 E:1409 ||| NN
of  ||| S:1409 E:1412 ||| IN
local  ||| S:1412 E:1418 ||| JJ
condition  ||| S:1418 E:1428 ||| NN
and  ||| S:1428 E:1432 ||| CC
faster  ||| S:1432 E:1439 ||| JJR
recovery ||| S:1439 E:1447 ||| NN
.  ||| S:1447 E:1449 ||| .
In  ||| S:1449 E:1452 ||| IN
this  ||| S:1452 E:1457 ||| DT
work  ||| S:1457 E:1462 ||| NN
the  ||| S:1462 E:1466 ||| DT
usage  ||| S:1466 E:1472 ||| NN
of  ||| S:1472 E:1475 ||| IN
carboxycysteine  ||| S:1475 E:1491 ||| VBG
to  ||| S:1491 E:1494 ||| TO
treat  ||| S:1494 E:1500 ||| VB
paranasal  ||| S:1500 E:1510 ||| JJ
sinus  ||| S:1510 E:1516 ||| JJ
conditions  ||| S:1516 E:1527 ||| NNS
has  ||| S:1527 E:1531 ||| VBZ
been  ||| S:1531 E:1536 ||| VBN
presented ||| S:1536 E:1545 ||| VBN
.  ||| S:1545 E:1547 ||| .
